公开(公告)号：US11828762B2

公开(公告)日：2023-11-28

申请号：US17096890

申请日：2020-11-12

申请人： Serimmune Inc.

发明人： Patrick Sean Daugherty ,  Kathryn Vinaya Louise Kamath ,  Jack Ryan Reifert

IPC分类号： G01N33/68 ,  C07K14/195 ,  C07K14/315 ,  C07K14/285 ,  C07K14/435 ,  C07K14/44 ,  C07K14/45 ,  G01N33/569 ,  G01N33/53 ,  G01N33/564 ,  C12N15/10 ,  C12Q1/689

CPC分类号： G01N33/6854 ,  C07K14/195 ,  C07K14/285 ,  C07K14/315 ,  C07K14/43554 ,  C07K14/44 ,  C07K14/45 ,  G01N33/53 ,  G01N33/564 ,  G01N33/569 ,  G01N33/56905 ,  G01N33/56911 ,  G01N33/56944 ,  G01N33/56966 ,  G01N33/56983 ,  G01N33/56988 ,  G01N33/56994 ,  G01N33/6842 ,  G01N33/6845 ,  G01N33/6878 ,  C12N15/1037 ,  C12Q1/689 ,  G01N2333/045 ,  G01N2333/05 ,  G01N2333/095 ,  G01N2333/16 ,  G01N2333/18 ,  G01N2333/20 ,  G01N2333/285 ,  G01N2333/29 ,  G01N2333/315 ,  G01N2333/4353 ,  G01N2570/00 ,  G01N2800/24 ,  G01N2800/26 ,  Y02A50/30

摘要： The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

公开(公告)号：US10012655B2

公开(公告)日：2018-07-03

申请号：US14532476

申请日：2014-11-04

申请人： INSTITUT PASTEUR

发明人： Marie-Lise Gougeon ,  Hela Saidi ,  Marie-Therese Melki ,  Beatrice Poirier-Beaudoin ,  Valerie Seffer

IPC分类号： G01N33/68 ,  A61K31/00 ,  A61K31/704 ,  G01N33/569

CPC分类号： G01N33/6875 ,  A61K31/00 ,  A61K31/704 ,  C12N2740/16011 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/4703 ,  G01N2800/52

摘要： Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.

公开(公告)号：US09889115B2

公开(公告)日：2018-02-13

申请号：US13933319

申请日：2013-07-02

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Board of Trustees of the University of Illinois

发明人： John W. Erickson ,  Sergei V. Gulnik ,  Hiroaki Mitsuya ,  Arun E. Ghosh

IPC分类号： A61K31/341 ,  A61K31/34 ,  A61K31/35 ,  A61K31/426 ,  A61K31/4523 ,  A61K31/4525 ,  A61K31/47 ,  C12Q1/02 ,  C12Q1/37 ,  A61K31/343 ,  A61K31/427 ,  A61K31/4725 ,  A61K31/496

CPC分类号： A61K31/341 ,  A61K31/34 ,  A61K31/343 ,  A61K31/35 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4523 ,  A61K31/4525 ,  A61K31/47 ,  A61K31/4725 ,  A61K31/496 ,  C12Q1/025 ,  C12Q1/37 ,  G01N2333/16 ,  G01N2333/8142 ,  Y02A50/411

摘要： The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R1, R2, R3, R5 or R6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO2; m is from 0 to 6; R4 is OH, ═O (keto), NH2, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO2. Optionally, R5 and R6, together with the N—W bond of formula (I), comprise a macrocyclic ring.

公开(公告)号：US20180002743A1

公开(公告)日：2018-01-04

申请号：US15625537

申请日：2017-06-16

申请人： JAN BIOTECH, INC.

发明人： Janet Lockwood Huie ,  Jennifer Anastasia Nichols ,  Deborah Allen Kuzmanovic

IPC分类号： C12Q1/68 ,  A61K31/404 ,  A61K31/7115

CPC分类号： C12Q1/6837 ,  A61K31/404 ,  A61K31/7115 ,  A61K31/713 ,  C12N2740/16052 ,  C12Q1/6818 ,  C12Q1/702 ,  C12Q1/703 ,  G01N2333/16 ,  Y02A50/391 ,  Y02A50/465 ,  C12Q2565/101

摘要： Disclosed are compositions, reagents, methods, assays, and kits for quantitative and sensitive detection of target ribonucleic acid (RNA) sequences, particularly target RNA sequences that contain RNA spliced sites, hairpin stem-loops or other topological configurations of RNA secondary, tertiary, and quaternary structure, as well as linear RNA sequences. In some embodiments, fluorogenic modified-backbone oligonucleotide probes are employed for specific sequence hybridization across the target site, followed by chemical autoligation to produce a fluorescent molecule within the ligated probes. The autoligation detection reaction is performed isothermally or through thermocycling.

公开(公告)号：US20170307613A1

公开(公告)日：2017-10-26

申请号：US15509841

申请日：2015-10-07

申请人： AVIOQ, INC

发明人： Chamroen CHETTY ,  Xing Xiang LI

IPC分类号： G01N33/569 ,  G01N33/00

CPC分类号： G01N33/56988 ,  G01N33/00 ,  G01N2333/16

摘要： The present invention discloses a method and its variations for simultaneous detection of antibodies against two or more antigens of human immunodeficiency virus (HIV) and determination of approximate time (duration) post HIV infection, thereby confirming the infection, and determination of recency of an HIV infection. The number of individuals with recently infected HIV in a given period may be further used to estimate incidence of HIV in a population.

公开(公告)号：US09581595B2

公开(公告)日：2017-02-28

申请号：US12527863

申请日：2008-02-26

申请人： Wei Huang ,  Signe Fransen ,  Christos Petropoulos ,  Jonathan Toma ,  Jeannette Whitcomb

发明人： Wei Huang ,  Signe Fransen ,  Christos Petropoulos ,  Jonathan Toma ,  Jeannette Whitcomb

IPC分类号： G01N33/00 ,  G01N33/569

CPC分类号： C12Q1/703 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  G01N2800/52

摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

摘要翻译： 本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。 在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性 艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。

公开(公告)号：US20160237121A1

公开(公告)日：2016-08-18

申请号：US15031232

申请日：2014-10-23

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICE

发明人： Yun-Xing Wang ,  Ping Yu

IPC分类号： C07K14/00 ,  A61K51/08 ,  A61K45/06 ,  A61K49/14 ,  A61K47/48 ,  A61K38/17 ,  G01N33/569 ,  A61K49/00

CPC分类号： C07K14/00 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/64 ,  A61K49/0056 ,  A61K49/14 ,  A61K51/088 ,  C12N2740/16011 ,  C12Q1/703 ,  G01N33/56988 ,  G01N2333/16

摘要： Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.

摘要翻译： 本文公开了结合HIV RRE RNA的化合物（例如肽或肽模拟物）。 在一些实例中，化合物抑制（例如降低）Rev与RRE RNA的结合。 在一些实施方案中，化合物包括两个部分，每个部分结合RRE中的一个Rev结合位点。 在一些实例中，部分包括肽或小分子。 在一些实例中，肽包括富含精氨酸的基序。 RRE结合化合物可以进一步连接到可检测标记或货物部分。 还公开了治疗或抑制HIV的方法，包括向受试者施用一种或多种所公开的化合物。

公开(公告)号：US09354230B2

公开(公告)日：2016-05-31

申请号：US12977271

申请日：2010-12-23

申请人： Eli N. Glezer ,  Kent Johnson ,  Michael Tsionsky ,  John H. Kenten ,  Jeff D. Debad ,  Robert M. Umek ,  Paula Denney Eason ,  Hans Biebuyck ,  Jacob N. Wohlstadter ,  James Wilbur ,  George Sigal ,  Niranjan Y. Sardesai

发明人： Eli N. Glezer ,  Kent Johnson ,  Michael Tsionsky ,  John H. Kenten ,  Jeff D. Debad ,  Robert M. Umek ,  Paula Denney Eason ,  Hans Biebuyck ,  Jacob N. Wohlstadter ,  James Wilbur ,  George Sigal ,  Niranjan Y. Sardesai

IPC分类号： G01N33/543 ,  C12Q1/48 ,  G01N33/68

CPC分类号： G01N33/5304 ,  C12Q1/485 ,  G01N33/54366 ,  G01N33/54373 ,  G01N33/5438 ,  G01N33/54386 ,  G01N33/56944 ,  G01N33/56983 ,  G01N33/56988 ,  G01N33/573 ,  G01N33/68 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6845 ,  G01N2333/11 ,  G01N2333/135 ,  G01N2333/16 ,  G01N2333/525 ,  G01N2333/5412 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/71 ,  G01N2333/9121 ,  Y10S436/807

摘要： Multiplexed test measurements are conducted using an assay module having a plurality of assay domains. In preferred embodiments, these measurements are conducted in assay modules having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence.

公开(公告)号：US20160018418A1

公开(公告)日：2016-01-21

申请号：US14851008

申请日：2015-09-11

申请人： INSTITUT PASTEUR

发明人： Marie-Lise Gougeon ,  Beatrice Poirier-Beaudoin ,  Valerie Seffer ,  Hela Saidi

IPC分类号： G01N33/68 ,  A61B5/055 ,  A61B5/15 ,  A61B5/00

CPC分类号： G01N33/6896 ,  A61B5/0042 ,  A61B5/055 ,  A61B5/15 ,  A61B5/4029 ,  A61B5/4064 ,  A61B5/407 ,  A61B5/4082 ,  A61B5/4088 ,  A61B2010/0077 ,  G01N33/56988 ,  G01N33/6854 ,  G01N2333/16 ,  G01N2333/52 ,  G01N2333/522 ,  G01N2333/523 ,  G01N2800/28 ,  G01N2800/56

摘要： The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

公开(公告)号：US20150330980A1

公开(公告)日：2015-11-19

申请号：US14383572

申请日：2013-03-07

申请人： SMART Biotech Ltd.

发明人： Tamar JEHUDA-COHEN

IPC分类号： G01N33/569 ,  C07K16/10 ,  C07K16/08

CPC分类号： G01N33/56983 ,  C07K16/08 ,  C07K16/082 ,  C07K16/1036 ,  C07K16/1045 ,  C07K16/109 ,  G01N2333/02 ,  G01N2333/15 ,  G01N2333/16 ,  G01N2333/186 ,  G01N2469/10 ,  G01N2469/20 ,  Y02A50/54

摘要： The invention relates to an improved assay for detecting antibodies in a tissue sample from individuals who test seronegative by conventional assay techniques, thus aiding in the diagnosis of possible pathogenic infections. Specifically, the invention relates to improved assay methods and kits that enable efficient detection of antibodies against a viral infection.

摘要翻译： 本发明涉及一种用于从通过常规测定技术测试血清阴性的个体的组织样品中检测抗体的改进测定法，从而有助于诊断可能的致病性感染。 具体地，本发明涉及能够有效检测针对病毒感染的抗体的改进的测定方法和试剂盒。